272 related articles for article (PubMed ID: 17937596)
21. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
22. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
23. Role of carbonate in the cytotoxicity of carboplatin.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2007 Jun; 20(6):896-904. PubMed ID: 17497898
[TBL] [Abstract][Full Text] [Related]
24. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
Rixe O
Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review.
Ferguson PJ
J Otolaryngol; 1995 Aug; 24(4):242-52. PubMed ID: 8551538
[TBL] [Abstract][Full Text] [Related]
26. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
27. β-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype.
Wu WJ; Zhang Y; Zeng ZL; Li XB; Hu KS; Luo HY; Yang J; Huang P; Xu RH
Biochem Pharmacol; 2013 Feb; 85(4):486-96. PubMed ID: 23219523
[TBL] [Abstract][Full Text] [Related]
28. The role of copper transporters in the development of resistance to Pt drugs.
Safaei R; Holzer AK; Katano K; Samimi G; Howell SB
J Inorg Biochem; 2004 Oct; 98(10):1607-13. PubMed ID: 15458823
[TBL] [Abstract][Full Text] [Related]
29. Clinical perspectives on platinum resistance.
Giaccone G
Drugs; 2000; 59 Suppl 4():9-17; discussion 37-8. PubMed ID: 10864226
[TBL] [Abstract][Full Text] [Related]
30. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
31. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
32. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
33. Polymorphic transporters and platinum pharmacodynamics.
Sprowl JA; Ness RA; Sparreboom A
Drug Metab Pharmacokinet; 2013; 28(1):19-27. PubMed ID: 22986709
[TBL] [Abstract][Full Text] [Related]
34. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family).
Yonezawa A; Masuda S; Yokoo S; Katsura T; Inui K
J Pharmacol Exp Ther; 2006 Nov; 319(2):879-86. PubMed ID: 16914559
[TBL] [Abstract][Full Text] [Related]
36. Platinum-based anticancer agents: innovative design strategies and biological perspectives.
Ho YP; Au-Yeung SC; To KK
Med Res Rev; 2003 Sep; 23(5):633-55. PubMed ID: 12789689
[TBL] [Abstract][Full Text] [Related]
37. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress.
Yamada M; Tomida A; Yun J; Cai B; Yoshikawa H; Taketani Y; Tsuruo T
Cancer Chemother Pharmacol; 1999; 44(1):59-64. PubMed ID: 10367750
[TBL] [Abstract][Full Text] [Related]
38. Platinum Antitumor Complexes: 50 Years Since Barnett Rosenberg's Discovery.
Muggia FM; Bonetti A; Hoeschele JD; Rozencweig M; Howell SB
J Clin Oncol; 2015 Dec; 33(35):4219-26. PubMed ID: 26503202
[No Abstract] [Full Text] [Related]
39. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
40. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistant cancer cell lines.
Liang XJ; Shen DW; Garfield S; Gottesman MM
Cancer Res; 2003 Sep; 63(18):5909-16. PubMed ID: 14522917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
